Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.39 |
| ▸ | IRAK3 | Q9Y616 | 2/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.38 |
| ▸ | CCNC | P24863 | 1/20 | 0.38 |
| ▸ | CDK8 | P49336 | 1/20 | 0.38 |
| ▸ | CLK1 | P49759 | 1/20 | 0.38 |
| ▸ | CLK2 | P49760 | 1/20 | 0.38 |
| ▸ | CDK7 | P50613 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13227538 | 1.00 | KDM4E (0.53) | KDM4EALDH1A1ALOX15KMT2AMEN1 | |
| SCHEMBL15508283 | 0.92 | CYP1A2 (0.52) | KDM4EALDH1A1ALOX15CYP1A2TDP1 | |
| Cyanide SCHEMBL27976810 | 0.86 | CYP1A2 (0.46) | KDM4EALDH1A1CYP1A2TDP1HRH3 | |
| SCHEMBL15450906 | 0.84 | KDM4E (0.51) | KDM4EALDH1A1ALOX15KMT2AMEN1 | |
| SCHEMBL18711627 | 0.84 | CYP1A2 (0.45) | CYP1A2TDP1HRH3KCNH2POLB | |
| SCHEMBL4550241 | 0.83 | POLB (0.50) | KDM4EALDH1A1CYP1A2TDP1HRH3 | |
| SCHEMBL13088446 | 0.83 | POLB (0.55) | KDM4EALDH1A1KMT2AMEN1CYP1A2 | |
| SCHEMBL19928661 | 0.82 | CYP1A2 (0.43) | KDM4EALDH1A1CYP1A2TDP1HRH3 | |
| SCHEMBL31397626 | 0.82 | CYP1A2 (0.43) | KDM4EALDH1A1CYP1A2TDP1HRH3 | |
| SCHEMBL27347094 | 0.82 | CYP1A2 (0.43) | KDM4EALDH1A1CYP1A2TDP1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE50030-E1 | Methods to treat lymphoplasmacytic lymphoma | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-10633348-B2 | Methods to treat lymphoplasmacytic lymphoma | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-04-28 | — | — | US | disclosed |
| US-10597387-B2 | Methods to treat lymphoplasmacytic lymphoma | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20180194739-A1 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | DANA-FARBER CANCER INSTITUTE, INC. | 2018-07-12 | — | — | US | disclosed |
| US-20180186780-A1 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-07-05 | — | — | US | disclosed |
| US-9908872-B2 | Methods to treat lymphoplasmacytic lymphoma | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-03-06 | — | — | US | disclosed |
| US-20130245013-A1 | STORAGE STABLE PERFUSION SOLUTION FOR DIHYDROPTERIDINONES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-09-19 | — | — | US | disclosed |
| US-8445675-B2 | Storage stable perfusion solution for dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-21 | — | — | US | disclosed |
| US-20120107312-A1 | Combinations for the Treatment of Diseases involving Cell Proliferation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-03 | — | — | US | disclosed |
| US-8143247-B2 | Combinations for the treatment of diseases involving cell proliferation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-27 | — | — | US | disclosed |
| US-20100249458-A1 | Process for the manufacture of dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-30 | — | — | US | disclosed |
| US-20100249412-A1 | Process for the manufacture of dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-30 | — | — | US | disclosed |
| US-7759485-B2 | Process for the manufacture of dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-20 | — | — | US | disclosed |
| US-7750152-B2 | Intermediate compounds for making dihydropteridinones useful as pharmaceutical compositions and processes of making the same | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-07-06 | — | — | US | disclosed |
| US-20090238828-A1 | Combinations for the Treatment of Diseases involving Cell Proliferation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-24 | — | — | US | disclosed |
| US-20090143379-A1 | Storage stable perfusion solution for dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-04 | — | — | US | disclosed |
| US-20080293944-A1 | Piperazinyl Compounds | ONCOHEROES BIOSCIENCES INC. | 2008-11-27 | — | — | US | disclosed |
| US-20080221099-A1 | DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES | ONCOHEROES BIOSCIENCES INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080177066-A1 | Process for the manufacture of dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-24 | — | — | US | disclosed |
| US-20080171747-A1 | Intermediate Compounds for making Dihydropteridinones Useful as Pharmaceutical Compositions | ONCOHEROES BIOSCIENCES INC. | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180186780-A1 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | IRAK1, IRAK4, IRAK2 | KDM4E 1254/4885ALDH1A1 4199/4885ALOX15 2999/4885 |
| US-20080221099-A1 | DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES | PLK4, TK1, POLK | KDM4E 4546/4885ALDH1A1 3183/4885ALOX15 2168/4885 |
| US-20120107312-A1 | Combinations for the Treatment of Diseases involving Cell Proliferation | CCNA1, MKI67, CCNA2 | KDM4E 4564/4885ALDH1A1 1053/4885ALOX15 1217/4885 |
| US-20180194739-A1 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | IRAK1, IRAK4, IRAK2 | KDM4E 1421/4885ALDH1A1 3752/4885ALOX15 1885/4885 |
| US-20090238828-A1 | Combinations for the Treatment of Diseases involving Cell Proliferation | CCNA1, MKI67, CCNA2 | KDM4E 4564/4885ALDH1A1 1053/4885ALOX15 1217/4885 |
| US-20100249458-A1 | Process for the manufacture of dihydropteridinones | QDPR, DHPS, DHODH | KDM4E 3687/4885ALDH1A1 731/4885ALOX15 1081/4885 |
| US-20090143379-A1 | Storage stable perfusion solution for dihydropteridinones | QDPR, F5, F12 | KDM4E 4832/4885ALDH1A1 1200/4885ALOX15 379/4885 |
| US-20080171747-A1 | Intermediate Compounds for making Dihydropteridinones Useful as Pharmaceutical Compositions | QDPR, DHPS, DHODH | KDM4E 4469/4885ALDH1A1 759/4885ALOX15 526/4885 |
| US-20080177066-A1 | Process for the manufacture of dihydropteridinones | QDPR, DHPS, DHODH | KDM4E 3687/4885ALDH1A1 731/4885ALOX15 1081/4885 |
| US-10633348-B2 | Methods to treat lymphoplasmacytic lymphoma | IRAK1, IRAK4, IRAK2 | KDM4E 1421/4885ALDH1A1 3752/4885ALOX15 1885/4885 |
| US-20130245013-A1 | STORAGE STABLE PERFUSION SOLUTION FOR DIHYDROPTERIDINONES | QDPR, F5, F12 | KDM4E 4832/4885ALDH1A1 1200/4885ALOX15 379/4885 |
| US-20080293944-A1 | Piperazinyl Compounds | QDPR, DHPS, DPYD | KDM4E 4088/4885ALDH1A1 709/4885ALOX15 1929/4885 |
| US-10597387-B2 | Methods to treat lymphoplasmacytic lymphoma | IRAK1, IRAK4, IRAK2 | KDM4E 1254/4885ALDH1A1 4199/4885ALOX15 2999/4885 |
| US-20100249412-A1 | Process for the manufacture of dihydropteridinones | QDPR, DHPS, DHODH | KDM4E 3687/4885ALDH1A1 731/4885ALOX15 1081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.